Today: 7 February 2026
Subscribe
Browse Category

NASDAQ:IBRX News 18 January 2026 - 1 February 2026

ImmunityBio stock jumps into the weekend as IBRX traders eye an FDA resubmission clock

ImmunityBio stock jumps into the weekend as IBRX traders eye an FDA resubmission clock

ImmunityBio shares (IBRX) closed Friday up 6% at $6.25, bucking broader market declines. The company faces dilution risk after amending a $505 million convertible note with Nant Capital. Attention is on FDA feedback for ANKTIVA’s label expansion in papillary bladder cancer, with a regulatory submission expected within 30 days. The next major event is the late-February ASCO GU conference.
1 February 2026
·····
ImmunityBio stock rebounds: FDA scrutiny, a $505 million note and the next catalyst for IBRX

ImmunityBio stock rebounds: FDA scrutiny, a $505 million note and the next catalyst for IBRX

ImmunityBio shares climbed 5.9% to $6.26 Friday, rebounding from early losses despite declines in major biotech ETFs. The move followed a STAT News report that Chairman Patrick Soon-Shiong misrepresented an FDA meeting on Anktiva’s label expansion. Investors also tracked dilution risk after ImmunityBio amended a $505 million convertible note to allow partial conversions into stock.
30 January 2026
·····
ImmunityBio (IBRX) stock slips after SEC filing tweaks $505 million insider note — what traders watch next

ImmunityBio (IBRX) stock slips after SEC filing tweaks $505 million insider note — what traders watch next

ImmunityBio shares fell 1.6% to $6.35 after a filing showed looser conversion terms on a $505 million note held by an affiliate of executive chairman Patrick Soon-Shiong. The amendment allows partial conversions into stock, raising dilution concerns. About 16.8 million shares traded as the stock ranged from $6.28 to $6.92. New glioblastoma data will be presented Jan. 31.
26 January 2026
·····
ImmunityBio stock tumbles after glioblastoma update; what to watch before Monday

ImmunityBio stock tumbles after glioblastoma update; what to watch before Monday

ImmunityBio shares fell 12.1% to $6.45 Friday after the company previewed new data from its Phase 2 glioblastoma trial, with full results due Jan. 31. The stock traded heavily between $7.88 and $6.43. Median overall survival in the study was “not yet reached” as of Jan. 22, with 19 of 23 patients alive. Investors are watching for more details on durability, safety, and trial design.
25 January 2026
·······
ImmunityBio (IBRX) stock slides after glioblastoma update — here’s what investors watch next week

ImmunityBio (IBRX) stock slides after glioblastoma update — here’s what investors watch next week

ImmunityBio shares fell 12.1% to $6.45 Friday after reporting median overall survival has not been reached in its Phase 2 glioblastoma trial. BTIG raised its price target to $9 and kept a Buy rating. The company said the FDA requested more data for its ANKTIVA bladder cancer application but no new trials. Preliminary 2025 net product revenue was reported at $113 million, up about 700% year-over-year.
24 January 2026
····
ImmunityBio stock price swings as new glioblastoma data hits; IBRX traders eye Jan. 31 update

ImmunityBio stock price swings as new glioblastoma data hits; IBRX traders eye Jan. 31 update

ImmunityBio shares rose 2.7% to $7.54 Friday after updated Phase 2 data showed 19 of 23 glioblastoma patients still alive, with median overall survival unreached. Over 31 million shares traded as investors awaited more trial details at a Jan. 31 summit. The company reported 2025 ANKTIVA revenue of $113 million and year-end cash of $242.8 million. The stock has tripled in three weeks.
23 January 2026
·····
ImmunityBio (IBRX) stock rises before the bell after FDA talks point to new ANKTIVA filing

ImmunityBio (IBRX) stock rises before the bell after FDA talks point to new ANKTIVA filing

ImmunityBio shares rose about 6.5% in premarket trading after the company said the FDA requested more data to support expanding ANKTIVA’s approved uses. ImmunityBio plans to submit the information within 30 days and does not expect to launch a new trial. Director Barry J. Simon disclosed recent stock sales. Traders are watching for the FDA’s response.
22 January 2026
·····
ImmunityBio stock price dips today as IBRX cools off after FDA resubmission update

ImmunityBio stock price dips today as IBRX cools off after FDA resubmission update

New York, January 21, 2026, 14:23 ET — Regular session ImmunityBio shares dropped roughly 2% to $6.35 in Wednesday afternoon trading, as investors pared back after the biotech’s recent regulatory update. The stock swung between $5.74 and $6.64, with around 67 million shares changing hands. The pullback is significant since the stock’s trajectory hinges on one key factor: how soon ImmunityBio can expand the U.S. label for Anktiva, its bladder-cancer immunotherapy on the market. A broader label would mean more patients gain access, especially in a treatment landscape that tightens quickly once standard options run out. ImmunityBio announced Tuesday that
21 January 2026
·····
ImmunityBio (IBRX) stock slips premarket after FDA maps fresh ANKTIVA resubmission route in bladder cancer

ImmunityBio (IBRX) stock slips premarket after FDA maps fresh ANKTIVA resubmission route in bladder cancer

New York, January 21, 2026, 08:47 EST — Premarket ImmunityBio’s stock dropped 5.9% to $6.10 in premarket trading Wednesday. The move followed the company’s announcement of a meeting with the U.S. Food and Drug Administration to discuss a possible resubmission of its bladder-cancer treatment, ANKTIVA. (MarketScreener) This move is significant because the FDA rejected ImmunityBio’s application last year to expand ANKTIVA for BCG-unresponsive papillary non-muscle invasive bladder cancer. The company is now making another attempt, claiming a clearer regulatory pathway. That strategy stands in contrast to Johnson & Johnson’s, which has focused on gathering randomized data before filing in the
21 January 2026
·····
ImmunityBio (IBRX) stock jumps on FDA’s 30-day ANKTIVA resubmission path — what’s next

ImmunityBio (IBRX) stock jumps on FDA’s 30-day ANKTIVA resubmission path — what’s next

New York, January 20, 2026, 20:22 ET — The market has closed. Shares of ImmunityBio, listed on Nasdaq, surged Tuesday following news that U.S. regulators outlined a potential path for the company to pursue an expanded bladder cancer indication for its drug ANKTIVA. The stock closed up 17.7% at $6.48, after trading between $4.94 and $7.97 on heavy volume. (Business Wire) Why it matters now: ANKTIVA stands as ImmunityBio’s flagship commercial product, with the company pushing to expand its label in a tough-to-treat segment of bladder cancer. A more defined path back to the FDA could reset timelines for how
21 January 2026
·····
ImmunityBio (IBRX) stock jumps after FDA signals ANKTIVA resubmission path in bladder cancer

ImmunityBio (IBRX) stock jumps after FDA signals ANKTIVA resubmission path in bladder cancer

New York, January 20, 2026, 12:42 ET — Regular session ImmunityBio, Inc. shares climbed roughly 24% to $6.82 by midday Tuesday after the company revealed the U.S. Food and Drug Administration provided guidance that could pave the way for a resubmission of its bladder cancer drug ANKTIVA. Earlier, the stock hit $7.97, fluctuating between $4.94 and $7.97 on about 159 million shares traded. (ImmunityBio) Why it matters now: this update puts a regulatory timeline back on the radar for patients with BCG-unresponsive papillary non-muscle invasive bladder cancer, a group often steered toward radical cystectomy, meaning bladder removal. That’s a definitive
20 January 2026
····
Why ImmunityBio stock jumped nearly 40%: ANKTIVA sales surge and a fresh trial timeline

Why ImmunityBio stock jumped nearly 40%: ANKTIVA sales surge and a fresh trial timeline

New York, Jan 18, 2026, 07:03 (EST) — Market closed ImmunityBio’s IBRX shares ended Friday at $5.52, jumping roughly 40% following a series of company updates that attracted momentum traders. Trading volume surged past 182 million shares. This shift is key as ImmunityBio heads into a shortened week, aiming to convert early interest in its first cancer drug into consistent revenue. Investors also received fresh insight on the company’s timeline for expanding ANKTIVA into a wider first-line bladder cancer market. ImmunityBio reported preliminary net product revenue of roughly $113 million for 2025 in a Friday release, with fourth-quarter revenue hitting
18 January 2026
·····
1 2

Stock Market Today

Northern Star Resources share price dips into weekend as $50m Central Tanami deal closes

Northern Star Resources share price dips into weekend as $50m Central Tanami deal closes

7 February 2026
Northern Star Resources fell 1.7% to A$26.77 Friday, extending losses as gold miners and the broader market declined. MGX Resources completed its A$50 million purchase of a 50% stake in the Central Tanami Gold Project from Northern Star. The All Ordinaries Gold index dropped 3.24%. CME Group raised COMEX gold futures margin requirements to 9% amid volatility.
PLS Group share price slips into weekend as Morgan Stanley and MUFG filings land

PLS Group share price slips into weekend as Morgan Stanley and MUFG filings land

7 February 2026
PLS Group shares closed at A$4.12 Friday, down 1.2% after a 3.7% drop Thursday. Morgan Stanley and Mitsubishi UFJ Financial Group disclosed increased voting power in the lithium miner, both citing changes dated Feb. 2. The moves came as lithium prices fell and Australian equities posted their sharpest drop in months. PLS reports interim results Feb. 19.
Commonwealth Bank share price near A$159 as CBA earnings, dividend week looms after ASX rout

Commonwealth Bank share price near A$159 as CBA earnings, dividend week looms after ASX rout

7 February 2026
Commonwealth Bank of Australia shares closed at A$158.91, down 0.23% Friday, as the S&P/ASX 200 fell 2.03% and nearly A$70 billion was wiped from the market. The bank reports half-year results and an interim dividend on Feb. 11, with shares going ex-dividend Feb. 18. CBA flagged a A$68 million provision linked to ASIC’s Better Banking review. The RBA raised rates to 3.85% on Feb. 3, with CBA passing on the increase from Feb. 13.
Go toTop